reports
- Sean Conroy
Hexima - Pezadeftide – a novel antifungal agent
Hexima is a pure-play biotech focused on the progression of its sole clinical asset, pezadeftide. The company aims to develop pezadeftide as a novel topical treatment for onychomycosis (fungal nail infection). Pezadeftide belongs to a novel class of molecules known as plant defensins, which are stable, soluble and possess antimicrobial activity. Following encouraging safety and efficacy results from randomised, double-blind, ascending dose-controlled Phase I/IIa trials, a Phase IIb clinical stud...
- Sean Conroy
Hexima - Pezadeftide – a novel antifungal agent
Hexima is a pure-play biotech focused on the progression of its sole clinical asset, pezadeftide. The company aims to develop pezadeftide as a novel topical treatment for onychomycosis (fungal nail infection). Pezadeftide belongs to a novel class of molecules known as plant defensins, which are stable, soluble and possess antimicrobial activity. Following encouraging safety and efficacy results from randomised, double-blind, ascending dose-controlled Phase I/IIa trials, a Phase IIb clinical stud...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.